Does molecular docking reveal alternative chemopreventive mechanism of activation of oxidoreductase by sulforaphane isothiocyanates Mazur P, Magdziarz T, Bak A, Chilmonczyk Z, Kasprzycka-Guttman T, Misiewicz-Krzemiska I, Skupiska K, Polanski J. Journal of Molecular Modeling 16(7):1205-12. FI: 2.336 (Q2) Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting Sánchez-Abarca LI, Gutiérrez-Cosio S, Santamaría C, Caballero-Velazquez T, Blanco B, Herrero-Sánchez C, García JL, Carrancio S, Hernández-Campo P, González FJ, Flores T, Ciudad L, Ballestar E, Del Cañizo C, San Miguel JF, Pérez-Simon JA. Blood 115(1):107-21. FI: 10.555 (Q1) P53 deletion may drive the clinical course and treatment response in multiple myeloma López-Anglada L, Gutiérrez NC, García JL, Mateos MV, Flores T, San Miguel JF. European Journal of Haematology 84(4):359-61. FI: 2.345 (Q3) Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy Cervera J, Montesinos P, Hernández Rivas JM, Calasanz MJ, Aventín A, Ferro MT, Luño E, Sánchez J, Vellenga E, Rayón C, Milone G, de la Serna J, Rivas C, González JD, Tormo M, Amutio E, González M, Brunet S, Lowenberg B, Sanz MA. Haematologica 95(3):424-31. FI: 6.416 (Q1) Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling Gutiérrez NC, Sarasquete ME, Misiewicz-Krzemiska I, Delgado M, De Las Rivas J, Ticona FV, Fermiñán E, Martín-Jiménez P, Chillón C, Risueño A, Hernández JM, García-Sanz R, González M, San Miguel JF. Leukemia 24(3):629-37. FI: 8.296 (Q1) Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: A pilot study on a series of 56 patients Cytometry Part B Matarraz S, López A, Barrena S, Fernandez C, Jensen E, Flores-Montero J, Rasillo A, Sayagues JM, Sánchez ML, Bárcena P, Hernández Rivas JM, Salvador C, Fernandez-Mosteirín N, Giralt M, Perdiguer L, Laranjeira P, Paiva A, Orfao A. Clinical Cytometry 78(3):154-68. FI: 1.727 (Q2) High-resolution genome-wide analysis of chromosomal alterations in elastofibroma García JL, Ortiz Rodríguez-Parets J, Valero JM, Gomez Muñoz MA, Benito R, Hernández Rivas JM, Bullón A. Virchows Archiv 456(6):681-7. FI: 2.305 (Q2) Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial Mateos MV, Oriol A, Martínez-López J, Gutiérrez NC, Teruel AI, de Paz R, García-Laraña J, Bengoechea E, Martín A, Mediavilla JD, Palomera L, de Arriba F, González Y, Hernández JM, Sureda A, Bello JL, Bargay J, Peñalver FJ, Ribera JM, Martín-Mateos ML, García-Sanz R, Cibeira MT, Ramos ML, Vidriales MB, Paiva B, Montalbán MA, Lahuerta JJ, Bladé J, Miguel JF. Lancet Oncology 11(10):934-41. FI: 14.470 (Q1) Monoclonal free light chains can be found in heavy chain diseases López-Anglada L, Puig N, Díez-Campelo M, Alonso-Ralero L, Barrena S, Aparicio MA, Gutiérrez NC, García-Sanz R. Annals of Clinical Biochemistry 47(Pt 6): 570-2. FI: 1.917 (Q2) Molecular analysis of ex-vivo CD133. GBM cells revealed a common invasive and angiogenic profile but different proliferative signatures among high grade gliomas BMC García JL, Pérez-Caro M, Gomez-Moreta JA, Gonzalez F, Ortiz J, Blanco O, Sancho M, Hernández Rivas JM, Gonzalez-Sarmiento R, Sánchez-Martín M. Cancer 10:454. FI: 2.736 (Q2)
|
